default author photo

Geeske F. Grit

Dutch Institute for Clinical Auditing

SCHOLARLY PAPERS

1

DOWNLOADS

143

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Real-World Overall Survival after Alternative Dosing for Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer: A Nationwide Retrospective Cohort Study with a Non-Inferiority Primary Objective

Number of pages: 26 Posted: 27 Feb 2024
Geeske F. Grit, Esmée van Geffen, Ruben Malmberg, Roelof W. F. van Leeuwen, Stefan Böhringer, Hans J. M. Smit, Pepijn Brocken, Job F. H. Eijsink, Esther Dronkers, Pim Gal, Eva Jaarsma, Regine J. H. M. van Drie-Pierik, Anne M. P. Eldering-Heldens, Machteld A. N. Wymenga, Peter G. M. Mol, Juliëtte Zwaveling and Doranne L. Hilarius
Dutch Institute for Clinical Auditing, LOGEX Healthcare Analytics, Erasmus University Rotterdam (EUR) - Erasmus Medical Center (MC), Erasmus University Rotterdam (EUR) - Erasmus Medical Center (MC), Leiden University - Leiden University Medical Center (LUMC), Rijnstate Hospital, Haga Hospital, Isala Hospital, LOGEX Healthcare Analytics, LOGEX Healthcare Analytics, LOGEX Healthcare Analytics, Medisch Spectrum Twente, Noordwest Ziekenhuisgroep, Medisch Spectrum Twente, affiliation not provided to SSRN, Leiden University - Leiden University Medical Center (LUMC) and Rode Kruis Ziekenhuis
Downloads 143 (514,995)

Abstract:

Loading...

Pembrolizumab, Non-Small Cell Lung Carcinoma, Non-Inferiority